January 20, 2026
Shady Grove Fertility: Cutting-Edge Research Boosts IVF Success
Shady Grove Fertility’s latest research reveals optimal medication dosing for IUI cycles to reduce multiple pregnancies and confirms equal IVF success rates for women with endometriosis using euploid blastocysts. A 20-year study of 8,911 patients found lower-dose clomiphene improves singleton outcomes.
Key Takeaways
Optimal IUI Medication Dosing Reduces Multiple Gestations
A 20-year study of 15,453 cycles found that a 50mg starting dose of clomiphene citrate (Clomid) increases singleton pregnancy chances compared to higher doses, minimizing twin/triplet risks. Lower medication doses do not compromise clinical pregnancy rates in ovulatory women.
Equal IVF Success Rates for Endometriosis Patients
Women with surgically confirmed endometriosis achieve comparable live birth rates via frozen embryo transfers using euploid blastocysts as patients with other infertility causes. The study challenges myths about IVF limitations for endometriosis patients.
Genetic Testing in IVF Benefits Endometriosis Patients
Preimplantation genetic testing (PGT-A) showed endometriosis patients produce euploid blastocyst rates equal to control groups. This confirms their embryos’ chromosomal quality is not inherently compromised by the condition.
Long-Term IUI Study Shows Clomid Efficacy
Analysis of 8,911 patients from 2004-2018 found clomid outperforms letrozole in reducing multiple pregnancies for ovulatory women. Both medications showed equivalent pregnancy rates but clomid better controls singleton outcomes.
Endometriosis Doesn’t Limit IVF Outcomes
Research partners with NIH confirmed endometriosis does not impair embryo quality or endometrial receptivity. Patients with endometriosis using euploid blastocysts have statistically identical live birth rates as non-infertile controls.
Source: Read full article